Phase 3 COMP360 Trial Achieves Key Depression Endpoint—Rapid and Durable Efficacy for Treatment-Resistant Patients
Major Clinical Milestone: COMP360 Demonstrates Consistent, Statistically Significant Benefit in Phase 3 TRD Studies
In a major advancement for mental health therapeutics, Compass Pathways (NASDAQ: CMPS) reported that its proprietary COMP360 psilocybin formula achieved the primary endpoint in the second of two pivotal Phase 3 trials for treatment-resistant depression (TRD). This marks the first time a classic psychedelic has shown consistent, highly statistically significant clinical results for this especially challenging patient group.
Rapid, Lasting Efficacy Signals New Hope for TRD Sufferers
The standout metric: Two fixed doses of 25mg COMP360 (given three weeks apart) compared with a 1mg control resulted in a mean difference of -3.8 points in the Montgomery-Åsberg Depression Rating Scale (MADRS) at the six-week mark—an effect size rarely seen in TRD trials. Rapid symptom reduction appeared as soon as the day following administration and was sustained through six weeks, with durability lasting at least 26 weeks for a sizable portion of participants in previous trials. Notably, 39% of patients in the Phase 3 COMP006 trial reached meaningful improvement (=25% reduction in MADRS) at six weeks, with earlier COMP005 results showing 25% achieving this benchmark—and over 40% of partial responders achieving full remission after a second dose.
| Trial | Treatment Arm | Mean Difference (MADRS) | Clinically Meaningful Reduction | p-value | Duration of Effect |
|---|---|---|---|---|---|
| COMP005 | 25mg vs Placebo | -3.6 | 25% @ 6 weeks | <0.001 | 26 weeks |
| COMP006 | 25mg vs 1mg | -3.8 | 39% @ 6 weeks | <0.001 | 26-week data expected Q3 2026 |
Safety Remains a Strength—Mild Side Effects and Low Serious Event Rates
Both studies confirm COMP360’s generally well-tolerated profile. Most side effects—including headache, nausea, or visual hallucination—were mild to moderate and quickly resolved (within a day for the majority). Serious adverse events were rare (2-5%), and the incidence of severe outcomes such as suicidal ideation or behavior was lower than 1% and limited to the control group for suicidal behavior. Independent review found no new safety concerns or imbalances between arms.
| Trial | Most Common TEAEs | % TEAEs Resolving Within a Day | % Serious Adverse Events (SAEs) |
|---|---|---|---|
| COMP005 (25mg) | Headache, Nausea, Visual Hallucination | 88% | 5% |
| COMP006 (25mg) | Headache, Nausea, Anxiety, Visual Hallucination | 83% | 2% |
Regulatory Path Forward: NDA Submission on the Horizon as TRD Market Awaits New Options
With these results, Compass Pathways is preparing for a meeting with the FDA to discuss a rolling submission and plans to complete its New Drug Application (NDA) in Q4. If approved, COMP360 would emerge as a first-in-class rapid-onset, durable treatment for the estimated 4 million people in the U.S. living with TRD—a population underserved by current therapies.
Investors and patients alike can track Compass’s progress at the upcoming management webcast on February 17th. Full 26-week efficacy data from the COMP006 trial is anticipated in early Q3 2026, further informing COMP360's potential to reset the standard of care for TRD. For a field long stalled by limited new options, these results point to a possible paradigm shift.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI